The NHS landscape is evolving rapidly as stakeholders seek to make the best use of scarce resources to achieve the best clinical outcomes for their patient populations.

While medicines clearly have a vital role to play in achieving these outcomes, it is becoming increasingly clear that even the most robust evidence base from the best-run clinical trials is no longer enough to guarantee the uptake and use of a new medicine.

Through strong partnerships, NHS stakeholders and pharmaceutical companies can ensure that patients gain access to and benefit from the most effective medicines and the NHS makes the best use of scarce resources.